A review in the Journal of Studies on Alcohol and Drugs associated buprenorphine to increased odds of treatment retention and opioid abstinence among adolescents with opioid use disorder, while methadone was tied to maintained treatment among those with heroin use disorder. Emerging data also showed the safety and feasibility of naltrexone for youths with OUD.
Buprenorphine, methadone, naltrexone may benefit teens with opioid use disorder
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.